Welcome to our News hub

Explore our own announcements in Press Releases.
Discover what others are saying about us in In The Media.

Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases

24-02-2026

Han forlod Novo for at bygge nyt fedmeselskab op fra bunden: “I sidste ende føles det helt rigtigt”

16-01-2026 MedWatch

$160 million Series A round for Alveus

08-01-2026 The Pharma Letter

Alveus Therapeutics exits stealth with $160M, developing an alternative to drugs like Ozempic

08-01-2026 Technical.ly

Alveus launches with $160M as newest start-up to step into obesity fray

08-01-2026 FirstWord Pharma

Obesity biotech Alveus gains $160M for push into MariTide’s backyard — and amylins

08-01-2026 Endpoint News

Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug

08-01-2026 BioSpace

Equipped with $160M series A, Alveus debuts into crowded obesity development landscape

08-01-2026 Fierce Biotech

Alveus Therapeutics, a Philadelphia start-up treating obesity, debuted with $160M in funding

08-01-2026 The Philadelphia Inquirer

Philadelphia VC firm creates obesity drug startup, raises $159.8M Series A

08-01-2026 Philadelphia Business Journal

Alveus raises $160M Series A for obesity drugs

08-01-2026 Axios

Biotech Alveus raises $160 million to tackle weight loss maintenance

08-01-2026 Reuters

Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity

23-01-2026

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases

08-01-2026